AG真人官方

STOCK TITAN

Dyne Therapeutics, Inc. SEC Filings

DYN NASDAQ

Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking a clinical-stage biotech can feel like decoding lab notes. Dyne Therapeutics鈥� SEC filings stretch across technical 10-Ks, rapid-fire 8-Ks on trial milestones, and daily Form 4 insider trades. Finding cash-runway details or deciphering collaboration clauses shouldn鈥檛 slow your research.

Stock Titan solves this problem. Our AI reads every Dyne Therapeutics document the moment it hits EDGAR, then delivers plain-English briefs so you can instantly answer questions such as 鈥渦nderstanding Dyne Therapeutics SEC documents with AI鈥� or 鈥淒yne Therapeutics insider trading Form 4 transactions.鈥� Whether you need the latest Dyne Therapeutics quarterly earnings report 10-Q filing or a Dyne Therapeutics 8-K material events explained, the platform keeps you current.

  • 10-K  Annual Report 鈥� Cash runway, R&D spend, and FORCE platform risks, with Dyne Therapeutics annual report 10-K simplified for quick review.
  • 10-Q  Quarterly Update 鈥� Revenue, expenses, and trial progress in a Dyne Therapeutics earnings report filing analysis.
  • 8-K  Material Events 鈥� AG真人官方-time alerts on clinical data releases and financing rounds.
  • Form 4 鈥� Dyne Therapeutics Form 4 insider transactions real-time so you can track executive stock transactions before the market reacts.
  • DEF 14A Proxy 鈥� Dyne Therapeutics proxy statement executive compensation distilled into clear metrics.

Every filing includes AI-powered summaries, keyword search, and side-by-side comparisons so you can monitor trial timelines, segment expenses, and 鈥淒yne Therapeutics SEC filings explained simply鈥� without wading through hundreds of pages.

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN) filed an 8-K stating that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to its investigational antisense oligonucleotide DYNE-251 for Duchenne muscular dystrophy patients amenable to exon 51 skipping. BTD provides earlier, more frequent FDA interactions and eligibility for priority review, potentially shortening time to market if efficacy and safety are confirmed. The filing furnishes, but does not file, the related press release as Exhibit 99.1 and contains no financial statements, trial data, or updated guidance. Management characterizes the event as material under Regulation FD, signaling strategic importance to Dyne鈥檚 pipeline and future revenue prospects, but investors must note that DYNE-251 still requires successful pivotal studies and eventual FDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

On 28 July 2025, Leslie鈥檚, Inc. (LESL) submitted a Form 8-K under Item 2.02 to furnish a press release (Exhibit 99.1) that contains estimated, preliminary financial results for its fiscal third quarter ended 28 June 2025. The actual figures are not included in the filing, and management cautions they may change once normal closing procedures and the external quarterly review are completed. Because the data remain preliminary, the information is deemed 鈥渇urnished鈥� rather than 鈥渇iled,鈥� limiting Section 18 liability and preventing automatic incorporation into future SEC documents. No other material events, transactions, or guidance updates are disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
current report
-
Rhea-AI Summary

Enterprise Financial Services Corp (EFSC) filed a Form 8-K to disclose that on 28 Jul 2025 it furnished a press release (Exhibit 99.1) announcing results for the quarter ended 30 Jun 2025. The Company will hold a live webcast on 29 Jul 2025 at 10:00 a.m. CT, accompanied by a slide deck (Exhibit 99.2). Both exhibits are being furnished, not filed, and therefore are excluded from incorporation into future Exchange Act reports.

No financial metrics, guidance, or additional corporate actions are included in the body of the report. Other disclosure items (registered securities table, emerging-growth-company checkboxes, signature block) reflect routine information with no changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
quarterly report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

LiveOne, Inc. (NASDAQ: LVO) has filed its Form 10-K for the fiscal year ended March 31 2025. The filing describes a multi-faceted media company built around four core operations: (1) the LiveOne live music streaming platform, (2) the Slacker audio membership service, (3) PodcastOne, and (4) Custom Personalization Solutions (CPS) for merchandising. Management groups PodcastOne and Slacker into an Audio Group, while all other units form the Media Group.

Business scale & reach

  • PodcastOne distributes more than 300 episodes weekly across 200 exclusive shows, reaching over 1 billion monthly listeners and generating 204 million downloads in FY 2025.
  • Slacker powers both the consumer LiveOne app and numerous OEM integrations (e.g., Tesla, Verizon, T-Mobile). One single OEM customer represented 鈮�45 % of consolidated FY 2025 revenue.
  • LiveOne owns or has pending 46 patents related to streaming technology and holds 25+ trademarks.

Revenue model: income is derived from (i) membership subscriptions (~50 % of FY25 revenue), (ii) advertising and sponsorships tied to music, livestreams and podcasts, (iii) pay-per-view events, and (iv) e-commerce merchandising via CPS.

Strategic initiatives

  • Continued expansion of proprietary CMS and analytics to improve ad targeting and creator reporting.
  • Launch of PodcastOne TV FAST channel and Adori visual podcast integration to open incremental video ad inventory.
  • Growth of a pay-per-view platform for digital-only concerts, introduced during the COVID-19 period.
  • Regular production of in-house franchises such as Music Lives, Self Made and the Breakout Awards.

Risks & controls

  • The report contains a going-concern warning; ongoing operations depend on additional capital or financing.
  • Significant customer concentration (one OEM at 45 %/51 % of revenue in FY25/FY24).
  • No auditor attestation of internal control over financial reporting (non-accelerated filer exemption).
  • LiveOne is not classified as a shell company; 97.1 million common shares were outstanding on 11 July 2025; public float value at 30 Sep 2024 was 鈮�$73 million.

Human capital: 113 employees at year-end with benefit programs (health, 401(k), EAP) and diversity initiatives. Remote-work flexibility adopted during COVID-19.

Regulatory landscape: the company licenses music through BMI, ASCAP, SoundExchange and operates under the Music Modernization Act. It notes compliance with FCPA, privacy regulations and multiple copyright regimes.

Forward look: management intends to combine live events, audio streaming and merchandising into a 鈥渇lywheel鈥� that monetises superfans; however, execution hinges on access to capital and maintaining content rights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Bitcoin Depot Inc. (Nasdaq: BTM) has filed a shelf registration statement on Form 424B5 allowing it to issue up to $100 million in securities, including Class A common stock, preferred stock, warrants and/or units, in one or more offerings. Specific terms, pricing and underwriters will be disclosed in future prospectus supplements.

Capital structure & potential dilution: The company currently has 22,555,710 Class A shares outstanding, 41,193,024 Class M shares (10 votes per share) controlled by the CEO, and 43,848,750 warrants exercisable at $11.50 until June 30 2033. Any issuance under the shelf could materially increase the public float and dilute existing holders, though proceeds will fund 鈥済eneral corporate purposes.鈥�

Business snapshot: Bitcoin Depot operates the largest Bitcoin ATM (BTM) network in North America with 8,483 kiosks and BDCheckout access in 10,926 retail locations as of March 31 2025. Q1 2025 revenue was $164.2 million, up from $138.5 million in Q1 2024, yet the company notes a 9.7 % revenue decline on a trailing-twelve-month basis despite a 15.7 % rise in Bitcoin prices, underscoring limited correlation between revenue and crypto price movements.

Key relationships & competitive position: The firm is the exclusive BTM provider for approximately 900 U.S. and Canadian Circle K stores and also licenses its BitAccess processing software to third-party operators, generating recurring software revenue.

Risk highlights (summarised from filing):

  • High dilution risk from additional equity or equity-linked issuances.
  • Complex, multi-class share structure with super-voting Class M and Class V shares.
  • Regulatory, competitive and litigation uncertainties outlined under 鈥淩isk Factors.鈥�
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
Rhea-AI Summary

Form 4 filed 07/01/2025: Atlassian Corporation (TEAM) Co-Founder, CEO, Director and 10% owner Michael Cannon-Brookes converted 490,560 Class B shares into Class A shares (Transaction Code C). The Class B shares were held by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust. The conversion was executed in connection with sales to be effected under a Rule 10b5-1 trading plan adopted on 02/20/2025.

Following the transaction, Cannon-Brookes鈥� reported holdings are:

  • Class A common stock: 490,560 shares (indirect)
  • Class B common stock (convertible one-for-one with no expiration): 48,024,933 shares (indirect)

No price was paid for the conversion (exercise price $0.00). The filing signals preparation for future open-market sales while complying with Section 16 reporting obligations and the updated Rule 10b5-1 affirmative-defense conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Morgan Stanley Finance LLC, guaranteed by Morgan Stanley (NYSE: MS), is marketing 鈥淲orst-of RTY & SPX Callable Jump Notes鈥� maturing 5 Aug 2030. The notes are linked to the Russell 2000 (RTY) and the S&P 500 (SPX) and offer 100 % participation in any positive performance of the worst-performing index, subject to the issuer鈥檚 right to call.

Early-redemption mechanism: starting 5 Aug 2026 and monthly thereafter (48 dates), the issuer will call the notes if a proprietary risk-neutral model indicates it is economic to do so. Investors receive a fixed 鈥渏ump鈥� payment that begins at $1,120 (12 % over par) and rises by $10 every month to $1,590 (59 % over par) by July 2030.

At maturity (if never called) investors receive: 鈥� par plus 100 % upside on the worst performer, capped only by the 59 % maximum shown in the hypothetical table; 鈥� full principal protection鈥攅ven if either index falls 100 %, payment is still $1,000. The notes pay no periodic coupons.

Key economics: issue price $1,000; estimated value $961.40 (approximately 3.9 % below par, reflecting structuring and hedging costs). CUSIP 61778NDQ1. The securities will not be exchange-listed; liquidity will depend on Morgan Stanley鈥檚 secondary market.

Principal risks detailed in the FWP include: call risk (upside cut off), no interest income, credit risk of Morgan Stanley, small-cap exposure via RTY, and potential adverse pricing in secondary trading. Investors should consult the full preliminary pricing supplement and tax discussion before investing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
prospectus

FAQ

What is the current stock price of Dyne Therapeutics (DYN)?

The current stock price of Dyne Therapeutics (DYN) is $10.05 as of August 1, 2025.

What is the market cap of Dyne Therapeutics (DYN)?

The market cap of Dyne Therapeutics (DYN) is approximately 1.4B.

What is the core focus of Dyne Therapeutics?

Dyne Therapeutics is focused on developing innovative therapeutics for genetically driven neuromuscular diseases using its proprietary FORCE platform.

How does the FORCE platform work?

The FORCE platform utilizes a modular design that links a therapeutic payload with a targeted antibody fragment to ensure effective delivery to muscle tissue and the central nervous system.

Which neuromuscular conditions does the company target?

The company targets conditions such as myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and is also exploring therapies for facioscapulohumeral muscular dystrophy (FSHD) and other rare muscle diseases.

What makes Dyne Therapeutics unique in its industry?

Its unique advantage lies in the innovative FORCE platform that overcomes delivery challenges in muscle tissue, combined with a deep scientific expertise and a robust pipeline focused on serious neuromuscular diseases.

How does Dyne Therapeutics generate value?

The company builds value through its research and development of targeted, molecular therapies that potentially modify the progression of debilitating muscle diseases, addressing a high unmet medical need.

What is the importance of targeted drug delivery in their approach?

Targeted drug delivery is crucial because it enhances the efficacy and safety of the therapeutic candidates by ensuring that active compounds reach affected tissues, such as skeletal muscle and the CNS, directly.

How does Dyne Therapeutics position itself within the competitive landscape?

It distinguishes itself through a focused, science-driven approach that combines innovative technology, a diverse pipeline, and rigorous clinical investigation, making it a key player in the field of neuromuscular therapeutics.
Dyne Therapeutics, Inc.

NASDAQ:DYN

DYN Rankings

DYN Stock Data

1.41B
132.26M
0.49%
88.46%
11.06%
Biotechnology
Pharmaceutical Preparations
United States
WALTHAM